TITLE

Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models?

AUTHOR(S)
Christen, Urs; Hintermann, Edith
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2007
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Autoimmune hepatitis (AIH) is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. The current treatment of autoimmune hepatitis is still largely dependent on the administration of corticosteroids and cytostatic drugs. For a long time the development of novel therapeutic strategies has been hampered by a lack of understanding the basic immunopathogenic mechanisms of AIH and the absence of valid animal models. However, in the past decade, knowledge from clinical observations in AIH patients and the development of innovative animal models have led to a situation where critical factors driving the disease have been identified and alternative treatments are being evaluated. Here we will review the insight on the immunopathogenesis of AIH as gained from clinical observation and from animal models.
ACCESSION #
120516830

 

Related Articles

  • Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis. Czaja, Albert J. // Current Pharmaceutical Design;10/1/2011, Vol. 17 Issue 29, p3120 

    Current corticosteroid regimens are effective in autoimmune hepatitis, but therapy can be complicated by side effects, disease progression, incomplete response, and relapse after drug withdrawal. The aims of this review are to describe the promising pharmacological, molecular and cellular...

  • Tumour microenvironment: Clearing the air for T cells. Villanueva, M. Teresa // Nature Reviews Cancer;Apr2015, Vol. 15 Issue 4, p199 

    Tghe artcile discusses the study "Immunological Mechanisms of the Antitumor Effects of Supplemental Oxygenation," by researcher S.M. Hatfield and colleagues, which reveal that mice with lung tumours given supplementary oxygen improve tumour oxygenation.

  • A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid. Joly, Pascal; Roujeau, Jean-Claude; Benichou, Jacques; Picard, Catherine; Dreno, Brigitte; Delaporte, Emmanuel; Vaillant, Loïc; D'Incan, Michel; Plantin, Patrice; Bedane, Christophe; Young, Paul; Bernard, Philippe // New England Journal of Medicine;1/31/2002, Vol. 346 Issue 5, p321 

    Background: Bullous pemphigoid is the most common autoimmune blistering skin disease of the elderly. Because elderly people have low tolerance for standard regimens of oral corticosteroids, we studied whether highly potent topical corticosteroids could decrease mortality while controlling...

  • Immunosuppressants.  // Reactions Weekly;7/26/2008, Issue 1212, p18 

    The article describes case studies involving four patients who developed nocardial infections while receiving immunosuppressive therapy for autoimmune disorders. Various immunosuppresants were being taken by the patients when they developed symptoms or signs of nocardial infections. It is...

  • Wegener's granulomatosis: treatment with cytotoxic agents and adrenocorticoids. Raitt, James W.; Raitt, J W // Annals of Internal Medicine;Mar71, Vol. 74 Issue 3, p344 

    Focuses on the treatment of Wegener's granulomatosis with adrenocorticoids and a cytotoxic drug. Measurement of the serum creatinine concentration; Findings of a biopsy of tissue sections of a typical skin lesion; Therapeutic use of prednisone therapy.

  • Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. Castelli, Chiara; Triebel, Frédéric; Rivoltini, Licia; Camisaschi, Chiara // OncoImmunology;Nov2014, Vol. 3 Issue 11, pN.PAG 

    We have recently reported that lymphocyte activation gene-3 (LAG-3,CD223) mediates the alternative, IFNα-deficient activation of plasmacytoid dendritic cells (pDCs) at tumor sites. Our findings define a novel tumor-driven strategy that promotes immunosuppression by pDCs, and we have provided...

  • Bullous pemphigoid occurring under anti-tumor necrosis factor-α therapy. Ricci, M.; Zauli, Stefania; Zelante, A.; Trevisani, L.; Virgili, A.; Bettoli, V. // International Journal of Colorectal Disease;Dec2014, Vol. 29 Issue 12, p1573 

    A letter to the editor is presented in response to the article "Bullous pemphigoid during long-term TNF- alpha blocker therapy" by M. Bordignon et al. in the June 2014 issue.

  • Treatment of IgG4-Related Disease. Kawano, Mitsuhiro; Yamada, Kazunori // Current Immunology Reviews;May2011, Vol. 7 Issue 2, p246 

    Corticosteroids are commonly used to treat autoimmune pancreatitis (AIP) and IgG4-related disease other than AIP, and a dramatic response is expected. Although spontaneous improvement is sometimes observed, steroid therapy is useful to relieve the clinical features including obstructive jaundice...

  • Disseminated cutaneous and visceral Kaposi's sarcoma in a patient with rheumatoid arthritis receiving corticosteroids and tacrolimus. Taniguchi, Takashi; Asano, Yoshihide; Kawaguchi, Makiko; Kogure, Asako; Mitsui, Hiroshi; Sugaya, Makoto; Sato, Shinichi // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2011, Vol. 21 Issue 3, p309 

    Kaposi's sarcoma (KS) is a vascular lesion of low-grade malignant potential caused by the complex interactions between geographic, genetic, environmental, and immunological factors. We recently experienced a rare case of KS associated with rheumatoid arthritis in a patient receiving...

  • Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Tsujimura, Shizuyo; Tanaka, Yoshiya // Clinical & Experimental Nephrology;Feb2012, Vol. 16 Issue 1, p102 

    Although corticosteroids, immunosuppressants and disease-modifying antirheumatic drugs (DMARDs) are widely used in the treatment of various systemic autoimmune diseases such as systemic lupus erythematosus (SLE), we often experience patients with systemic autoimmune diseases who are resistant to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics